You are here

Article Text

Article menu
Download PDFPDF
Online mutation report
Novel TBX5 mutations and molecular mechanism for Holt-Oram syndrome
  1. C Fan1,
  2. M A Duhagon1,2,
  3. C Oberti2,
  4. S Chen1,
  5. Y Hiroi3,
  6. I Komuro4,
  7. P I Duhagon2,
  8. R Canessa2,
  9. Q Wang1
  1. 1Center for Molecular Genetics, Department of Molecular Cardiology, Lerner Research Institute, and Center for Cardiovascular Genetics, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
  2. 2Instituto de Cardiologia Infantil, Hospital Italiano, Ospedale Italiano Umberto 15, Montevideo, Uruguay
  3. 3Department of Cardiovascular Medicine, University of Tokyo Graduate School of Medicine, Tokyo, Japan
  4. 4Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan
  1. Correspondence to:
 Dr Q Wang, Center for Molecular Genetics/ND4-38, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA;
 wangq2{at}ccf.org

https://doi.org/10.1136/jmg.40.3.e29

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The Holt-Oram syndrome (OMIM 142900) is an autosomal dominant disorder with clinical features characterised by a variety of skeletal malformations and congenital heart defects.1–5 The gene for Holt-Oram syndrome has been identified as TBX5 on chromosome 12q24.6–11TBX5 encodes a protein of 518 amino acids that belongs to the family of the T box transcriptional factors,10,11 and is expressed in embryonic heart and limb tissues, consistent with its involvement in development of the heart and skeletal structures.12–17 TBX5 contains a highly conserved DNA binding domain, the T box domain. Recently, three groups have provided direct evidence that TBX5 can bind to DNA and activate transcription of its target genes including the gene for atrial natriuretic factor (ANF).17–19 Furthermore, TBX5 can interact directly with the cardiac homeobox protein NKX2.5 synergistically to activate transcription of ANF.17,18

    To date, 22 different non-translocation TBX5 mutations have been reported. These include five truncations (nonsense mutations), three splicing changes, six frameshift mutations, seven missense mutations, and one large deletion involving exons 3-9.20–22 Frameshift, splicing, and nonsense mutations are expected to produce truncated TBX5 or no TBX5 at all (for example, via nonsense mediated mRNA decay), which causes Holt-Oram syndrome by haploinsufficiency. However, the mechanisms by which the missense mutations cause Holt-Oram syndrome are not well understood. Ghosh et al19 found that missense mutations G80R and R237Q eliminated DNA binding, whereas mutations G169R and S252I did not affect DNA binding. Hiroi et al18 analysed the effect of G80R and R237Q on transcription activity of the ANF promoter. Mutation G80R caused significant reduction of transcriptional activation activity of TBX5 and loss of synergistic activation with NKX2.5. Surprisingly, mutation R237Q, which eliminated DNA binding, had minor effects on transcriptional activation.18 …

    View Full Text